Otter Creek Advisors’s Immunic IMUX Stock Holding History

Otter Creek Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,200	Closed	-$910K	–	49
2022 Q1	$1.6M	Buy	14,200 +2,200	+18%	+$255K	0.65%	49
2021 Q4	$1.15M	Buy	12,000 +2,000	+20%	+$180K	0.74%	40
2021 Q3	$885K	Buy	10,000 +5,000	+100%	+$492K	0.47%	36
2021 Q2	$613K	Buy	5,000 +1,500	+43%	+$207K	0.27%	42
2021 Q1	$558K	Buy	+3,500	New	+$594K	0.37%	43

Other funds holding IMUX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Otter Creek Advisors's IMUX Position: Q2 2022 in Review

Otter Creek Advisors sold out of Immunic (IMUX) in Q2 2022, closing a stake of 14,200 shares — an estimated $910K sold.

Otter Creek Advisors first reported a position in IMUX in Q1 2021 and held it in 5 quarters. The position peaked at $1.6M in Q1 2022. 72 funds tracked by Wall St. Rank hold IMUX as of Q2 2022.

Otter Creek Advisors reported no remaining Immunic position as of Q2 2022 after selling out during the quarter.
Otter Creek Advisors sold 14,200 Immunic shares in Q2 2022, an estimated $910K.
Otter Creek Advisors first reported a position in Immunic in Q1 2021 and held it in 5 quarters.
Otter Creek Advisors's Immunic position peaked at $1.6M in Q1 2022.
72 funds tracked by Wall St. Rank held Immunic as of Q2 2022.

Based on Otter Creek Advisors's 13F filing for Q2 2022, filed 8 Aug 2022.